| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | FIMM | pan-cancer | AAC | -0.097 | 0.6 |
| mRNA | BRD-K16147474 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.6 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.6 |
| mRNA | Axitinib | FIMM | pan-cancer | AAC | -0.086 | 0.6 |
| mRNA | Crizotinib | CCLE | pan-cancer | AAC | 0.022 | 0.6 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | 0.015 | 0.7 |
| mRNA | navitoclax:MST-312 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.018 | 0.7 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
| mRNA | JQ-1 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |